Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615836 | 0.92 | LMNA (0.44) | GAAHPGDLMNAMAPK1HTT | |
| SCHEMBL14403245 | 0.79 | DRD2 (0.39) | GAASLC6A3SLC6A4ALDH1A1 | |
| SCHEMBL615307 | 0.79 | CCR2 (0.36) | GAAHPGDLMNAMAPK1HTT | |
| SCHEMBL3934115 | 0.79 | SLC6A3 (0.48) | GAAHPGDLMNANPSR1SLC6A3 | |
| SCHEMBL11041015 | 0.78 | GAA (0.44) | GAAHPGDLMNANPSR1SLC6A3 | |
| Hydrochloric Acid SCHEMBL4257944 | 0.78 | SLC6A3 (0.47) | GAAHPGDLMNANPSR1SLC6A3 | |
| SCHEMBL615579 | 0.78 | DRD2 (0.50) | GAALMNAMAPK1HTTNPSR1 | |
| SCHEMBL615620 | 0.76 | GAA (0.53) | GAALMNAMAPK1HTTNPSR1 | |
| Hydrochloric Acid SCHEMBL6734307 | 0.76 | DRD2 (0.49) | GAALMNAMAPK1HTTNPSR1 | |
| SCHEMBL12526220 | 0.75 | HTR1D (0.52) | MEN1ALDH1A1KMT2AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10882856-B2 | 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases | BEIGENE, LTD. (KY) | 2021-01-05 | — | — | US | disclosed |
| WO-2018054365-A1 | NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES | BEIGENE, LTD. (KY) | 2018-03-29 | — | — | WO | disclosed |
| EP-2419419-B1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-03 | — | — | EP | disclosed |
| EP-2419419-B1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-03 | — | — | EP | disclosed |
| US-8513229-B2 | 4-Azetidinyl-1-phenyl-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-20 | — | — | US | disclosed |
| US-8513229-B2 | 4-Azetidinyl-1-phenyl-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-20 | — | — | US | disclosed |
| US-8513229-B2 | 4-Azetidinyl-1-phenyl-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-20 | — | — | US | disclosed |
| WO-2013010453-A1 | CHEMOKING RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | WO | disclosed |
| EP-2419419-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2012-02-22 | — | — | EP | disclosed |
| US-20120040960-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-16 | — | — | US | disclosed |
| US-6153611-A | AS NON-DOPAMINERGIC ANTIISCHEMIC COMPOUNDS FOR TREATING BRAIN DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-11-28 | — | — | US | disclosed |
| US-5658941-A | PSYCHOLOGICAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| US-5595993-A | Antischemic piperazinyl- and piperidinyl-cyclohexanes | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-01-21 | — | — | US | disclosed |
| EP-0546583-B1 | Piperazinyl-and piperidinyl-cyclohexanols | BRISTOL MYERS SQUIBB CO (US) | 1996-05-22 | — | — | EP | disclosed |
| US-5496847-A | ANXIOLYTIC AND ANTIDEPRESSANT | BRISTOL-MYERS SQUIBB CO. (US) | 1996-03-05 | — | — | US | disclosed |
| US-5478828-A | Anxiolytic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-12-26 | — | — | US | disclosed |
| US-5391570-A | Anxiolytic agents; antidepressants | BRISTOL-MYERS SQUIBB (US) | 1995-02-21 | — | — | US | disclosed |
| US-5387593-A | Anxiolytic agents | BRISTON-MYERS SQUIBB (US) | 1995-02-07 | — | — | US | disclosed |
| US-5352678-A | Dopaminergic agents | BRISTOL-MYERS SQUIBB CO. (US) | 1994-10-04 | — | — | US | disclosed |
| EP-0546583-A1 | Piperazinyl-and piperidinyl-cyclohexanols | Bristol-Myers Squibb Company (US) | 1993-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882856-B2 | 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases | IDO1, TPH1, IDO2 | GAA 929/4885HPGD 135/4885LMNA 4032/4885 |
| US-20120040960-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | GAA 3203/4885HPGD 821/4885LMNA 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.